MCKESSON CORP Quarterly Report Released - Here’s What You Should Know

McKesson Corporation Quarterly Financial Summary – June 30, 2025

Key Financial Metrics

• Revenues: $97.8 billion (up 23% from $79.3 billion in Q1 FY2024)
• Gross Profit: $3.28 billion (up 4% from $3.15 billion)
• Gross Profit Margin: 3.35% (down from 3.98%)
• Net Income (Attributable to McKesson): $784 million (down 14% from $915 million)
• Diluted Earnings Per Share: $6.25 (down from $7.00)
• Operating Income: $1.04 billion (flat vs. $1.03 billion)
• Operating Expenses: $2.24 billion (up 6%)
• Cash and Cash Equivalents: $2.42 billion (down from $5.69 billion on March 31, 2025)
• Long-Term Debt: $6.53 billion (up from $4.46 billion)
• Total Litigation Liabilities: $6.38 billion (unchanged from March 31, 2025)
• Dividend Raised: Quarterly dividend increased from $0.71 to $0.82 per share as of July 29, 2025
• Share Repurchases: 0.8 million shares repurchased during the quarter for $590 million at an average price of $709.84/share

Segment Performance

• U.S. Pharmaceutical: Revenue $89.95 billion (+25%), operating profit $727 million (-7%)
• Prescription Technology Solutions: Revenue $1.43 billion (+16%), operating profit $253 million (+25%)
• Medical-Surgical Solutions: Revenue $2.70 billion (+2%), operating profit $221 million (+18%)
• International: Revenue $3.74 billion (+1%), operating profit $92 million (+2%)

Notable Events and Initiatives

• Acquisition of PRISM Vision Holdings, LLC (closed April 1, 2025, $874 million in cash; $432 million in goodwill, $510 million in finite-lived intangibles)
• Acquisition of Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) (closed June 2, 2025, $2.5 billion in cash; $806 million in goodwill, $2.3 billion in finite-lived intangibles)
• Announced intention to separate the Medical-Surgical Solutions segment
• New senior unsecured credit facility ($1.0 billion, 364-day facility) entered in May 2025
• Issued $650 million in 4.65% Notes due 2030, $650 million in 4.95% Notes due 2032, and $698 million in 5.25% Notes due 2035 in May 2025

Liquidity and Capital Resources

• Net cash used in operating activities improved to $(918) million, compared to $(1.38) billion in the prior year’s quarter
• Investing activities used $3.56 billion (mainly for acquisitions)
• Financing activities provided $1.18 billion (includes debt issuance, share repurchases, and dividend payments)
• Working capital at June 30, 2025 was negative $7.53 billion (down from negative $6.21 billion at March 31, 2025)
• Debt-to-capital ratio decreased to 115.9% from 125.3% at March 31, 2025

Risks

• Opioid Litigation Exposure: McKesson continues to face substantial litigation liabilities relating to opioid distribution, with $6.38 billion in litigation liabilities outstanding. Active litigation includes ongoing claims from the City of Baltimore, Philadelphia, and various Canadian plaintiffs. Although payments totaling $497 million were made in July for settlements, significant future liability remains.
• Customer Credit Risk: The bankruptcy of Rite Aid in May 2025 led to a $189 million provision for bad debts this quarter, evidencing ongoing counterparty risk and the impact of major customer financial distress.
• Regulatory and Legal Proceedings: The company is subject to routine subpoenas, investigations, and claims, including pending opioid-related lawsuits in the U.S. and Canada, and ongoing proceedings related to the New York Opioid Stewardship Act where $42 million has already been paid.
• Integration of Acquisitions: Large recent acquisitions (PRISM Vision, Core Ventures) add integration risks, with $1.24 billion of new goodwill added to U.S. Pharmaceutical segment alone this quarter.
• Debt and Liquidity Management: Long-term debt increased to $6.53 billion from $4.46 billion, and net cash outflows continue largely due to acquisition activity, requiring continued monitoring of leverage and liquidity ratios.

Management Discussion and Outlook

• Revenue and gross profit benefited from recent acquisitions and core growth, particularly in the U.S. Pharmaceutical and Prescription Technology Solutions segments.
• Despite increased revenues and operating income, net income and EPS declined due to a higher provision for doubtful accounts ($189 million, directly tied to Rite Aid bankruptcy) and a higher reported income tax rate (20.9% vs 11.4%).
• The company continues to undergo restructuring initiatives, with $47 million in restructuring, impairment, and related charges this quarter aimed at enterprise-wide modernization and cost efficiency.
• Capital deployment remains focused on shareholder returns (dividends + share repurchases = $671 million in Q1) and strategic M&A.
• Management believes liquidity is sufficient due to operational cash flow, available credit, and strong access to capital markets, but warns of significant uncertainties associated with litigation outcomes and customer credit exposures.
• The announced intention to separate Medical-Surgical Solutions may be a key catalyst in the coming periods.

Investor Takeaways

McKesson delivered strong revenue growth on the back of large acquisitions and healthy segment performance, but faces margin pressure, higher credit risk, and ongoing heavy litigation exposure. Income and EPS declined despite top-line gains due to one-time charges and increased tax rate. The company is aggressively deploying capital for growth and shareholder returns, but the integration of new acquisitions and management of legal risks remain critical areas to monitor for forward performance.

Visit Publicview AI to search and analyze millions of SEC filings using AI.